Your session is about to expire
← Back to Search
Viral Therapy for Cancer
Study Summary
This trial is testing if a combination of three viruses can help treat cancer by shrinking tumours. The viruses are given one after the other, with the AdMA3 virus given first. It is not known if this treatment will be more effective than standard cancer treatments.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Arm B- AdMA3 (vaccine prime) alone
- Group 2: Arm C- AdMA3 plus MG1MA3 (prime + boost)
- Group 3: Arm A (MG1MA3 virus alone)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many study participants are currently being treated with this medication?
"Unfortunately, this trial is no longer looking for volunteers. The study was first posted on 10/31/2014 and was last updated on 9/28/2022. However, there are other clinical trials you might be eligible for- currently, 22 studies for adenoviridae infections and 2 MG1MA3 studies are actively recruiting participants."
What are the goals of this research project?
"The purpose of this three-year clinical trial is to study the Objective tumour response rate (ORR) of patients using RECIST v1.1. Additionally, the Phase I: MG1MA3 clearance and secondary replication from pharmacokinetics and viral shedding, as well as toxicity inPhase II: AdMA3-related adverse events, and Phase II: pharmacokinetics (PK) of MG1MA3 (MG1MA3 clearance and secondary replication (genomes and infectious units)) will be observed and recorded."
What similar projects to MG1MA3 have been completed in the past?
"The first study of MG1MA3 took place in 2014 at BCCA - Vancouver Cancer Centre. In the years since, there have been a total of 11 completed clinical trials. As of now, 2 studies are still ongoing; both based in Toronto, Ontario."
In how many different medical clinics is this study being run today?
"Currently, there are 4 locations running this study: University Health Network in Toronto; Ottawa Hospital Research Institute in Ottawa; Juravinski Cancer Centre at Hamilton Health Sciences in Hamilton. Plus, there are 4 other locations."
Are there any places still open for volunteers in this experiment?
"According to the latest update on clinicaltrials.gov, this study is not currently enrolling patients. Although the trial was originally posted on October 31st, 2014, it was last updated September 28th, 2022. There are 24 other trials that are still recruiting patients."
Share this study with friends
Copy Link
Messenger